


Sonify Biosciences

Alexandria LaunchLabs - Sonify Biosciences
 430 E. 29th Street, 14th Floor
 New York, NY 10016

Dr. Miriam S. Boer, Founder
 T 845-729-2353
www.sonifybio.com
info@sonifybio.com



<p>Industry: <input type="checkbox"/> Pharma <input type="checkbox"/> Biotech <input checked="" type="checkbox"/> Medical Device <input type="checkbox"/> Diagnostic <input type="checkbox"/> Other (declare)</p> <p>Management: Founder: • Dr. Miriam S. Boer, PhD. Advisors: • Dr. Daniel Rogers, PhD. • Dr. Zeljko Vujaskovic, MD, PhD. • Prof. Paul Stauffer, MSEE, CCE • Dr. Rena Lapidus, PhD</p> <p>Number of Employees: 1</p> <p>Finance: Sonify has raised just shy of \$500k of angel investment and is currently looking to raise \$3-5M.</p> <p>Legal: Corporate: Mark Kass at Crowell & Moring. Intellectual Property: David Resnick at Nixon Peabody</p>

Executive Summary:

Sonify is developing a noninvasive device that uses ultrasound to gently heat and treat a wide array of superficial tumors. This gentle heat treatment is called hyperthermia; it is a proven therapy and is fully covered by Medicare and commercial payers.

Company History:

Founded in 2012 by Dr. Miriam S. Boer, Sonify is building a better hyperthermia device. Sonify recently relocated to New York from Baltimore, MD to join the Alexandria LaunchLabs incubator.

Market Opportunity:

Hyperthermia devices on the market do not meet the needs of the radiation oncologists who use them. As a direct result of underperforming equipment, less than 1% of eligible insured patients receive this lifesaving therapy.

Product:

Sonify is developing a device that delivers hyperthermia treatments accurately and reliably in a cost-effective and user-friendly package. We are working with some of the world's leading hyperthermia experts to ensure Sonify's device addresses their needs and surpasses competing technology.

Milestones:

Sonify's data shows our heating module and temperature feedback module functioning. Current fundraising efforts will bring them together to build a bedside prototype, to be tested on animals first and then used for clinical trials.

Intellectual Property:

Sonify's IP is protected domestically and abroad. All intellectual property was developed by and is wholly owned by Sonify.

Competitive technology:

Current technological limitations are the reason why hyperthermia is used on less than 1% of eligible patients for whom the procedure is covered. There is no single device on the market that is noninvasive, accurate, and reliable as well as user-friendly and cost-effective.

Finances:

Sonify will be in an engineering-heavy phase in the near future, followed by entrance into the regulatory process with the FDA. We expect to begin selling devices by the latter half of 2021.

Please indicate primary purpose of Presentation:

Investment

Business Development

Other: (Please specify)